Beam Therapeutics (BEAM) Non Operating Investment Income (2020 - 2026)
Beam Therapeutics (BEAM) posted quarterly Non Operating Investment Income of $16000.0 for Q1 2026, up 100.77% year-over-year from $7969.4 in Q1 2025, and up 100.48% quarter-over-quarter from -$3.3 million in Q4 2025.
Powered by 
Analysis
Beam Therapeutics (BEAM) Non Operating Investment Income (2020 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported Non Operating Investment Income for 7 consecutive years, with $16000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income rose 100.77% year-over-year to $16000.0; the TTM figure through Mar 2026 stood at $6.0 million (up 147.1% YoY), while the FY2025 annual figure was $3.9 million, up 127.97% from the prior year.
- Non Operating Investment Income improved to $16000.0 in Q1 2026 per BEAM's latest filing, from -$3.3 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $21.6 million in Q4 2022 and bottomed at -$12.8 million in Q1 2023.
- Historically, Non Operating Investment Income has averaged -$501588.2 across 5 years, with a median of -$2.1 million in 2024.
- On a YoY basis, Non Operating Investment Income climbed as much as 605.34% in 2022 and fell as far as 839.65% in 2022.
- Beam Therapeutics' Non Operating Investment Income stood at $21.6 million in 2022, then slumped by 103.35% to -$722000.0 in 2023, then tumbled by 50.97% to -$1.1 million in 2024, then tumbled by 205.41% to -$3.3 million in 2025, then soared by 100.48% to $16000.0 in 2026.
- Business Quant data shows BEAM's Non Operating Investment Income at $16000.0 in Q1 2026, -$3.3 million in Q4 2025, and $4.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | 338,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 338,000.00 |
| Mar 31, 2026 | 16,000.00 |
| Dec 31, 2025 | -3.33 Mn |
| Sep 30, 2025 | 4.94 Mn |
| Jun 30, 2025 | 4.42 Mn |
| Mar 31, 2025 | -2.08 Mn |
| Dec 31, 2024 | -1.09 Mn |
| Sep 30, 2024 | -2.06 Mn |
| Jun 30, 2024 | -7.59 Mn |
| Mar 31, 2024 | -3.35 Mn |
| Dec 31, 2023 | -722,000.00 |
| Sep 30, 2023 | -11.22 Mn |
| Jun 30, 2023 | 6.15 Mn |
| Mar 31, 2023 | -12.80 Mn |
| Dec 31, 2022 | 21.58 Mn |
| Sep 30, 2022 | 10.43 Mn |
| Jun 30, 2022 | -4.12 Mn |
| Mar 31, 2022 | -7.69 Mn |
| Dec 31, 2021 | -4.27 Mn |
| Sep 30, 2021 | -4.89 Mn |